PORCN抑制剂;PORCN Inhibitors;;InformationETC-159 ETC-159 (ETC-1922159) is an orally available, potent porcupine inhibitor with an IC50 of 2.9 nM for inhibiting β-catenin reporter activity in STF3A cells.TargetsPorcnIn vitroETC-159 treatment causes decreased abundance of Wnt3a-stabilized β-catenin protein in both mouse L cells and HEK293 cells. ETC-159 inhibits β-catenin signaling in response to multiple active Wnts. ETC-159 inhibits mouse PORCN with an IC50 of 18.1\u2009nM, whereas the IC50 for Xenopus Porcn is approximately fourfold higher (70\u2009nM).In vivoETC-159 is orally bioavailable and effectively inhibits the growth of mouse mammary tumor virus-Wnt1 tumors. After a single oral dose of 5\u2009mg/kg in mice, ETC-159 is rapidly absorbed into the blood with a Tmax of ~0.5\u2009h and oral bioavailability of 100%. The plasma half-life is ~1.18\u2009h and its concentration in the blood remained above the in vitro IC50 for at least 16\u2009h. Treatment of mice with increasing doses of ETC-159 leads to a dose-related increase in exposure. ETC-159 also effectively inhibits Wnt autocrine signaling and growth of teratocarcinomas. ETC-159 effectively inhibits the growth and induces differentiation of colon cancers with RSPO translocations and induces global remodeling of gene expression. Suppression of Wnt/β-catenin signaling with ETC-159 in genetically defined tumors induces irreversible cellular differentiation thus preventing regrowth of these tumors.Cell Research(from reference)Cell lines:Mouse L cells Concentrations:100\u2009nM Incubation Time:0-24 h